Daily Pill Clears Tumours in One in 12 Pancreatic Cancer Patients in Early Trial

Illustration of the human pancreas, the organ affected by pancreatic cancer. Illustration: Ryan Kissinger / NIAID, public domain

A daily pill combined with chemotherapy has produced results that cancer specialists are calling the biggest advance in pancreatic cancer treatment for decades, with tumours shrinking or disappearing in most of the patients who took it in an early trial.

The drug, daraxonrasib, was given alongside standard chemotherapy to 61 people whose pancreatic cancer had recently been diagnosed and had already spread beyond the pancreas. In 60.7 per cent of them, tumours shrank or vanished altogether, and in 8.2 per cent — roughly one in 12 — scans showed no sign of the cancer at all.

The findings were presented on Friday at the EORTC-NCI-AACR cancer symposium in Barcelona by Dr Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Center in New York, who led the trial. “In about one in 12 patients, it completely disappeared,” he told the Press Association, calling the results “a massive, massive breakthrough” in treating the disease.

Tumours stopped growing in 90.2 per cent of the patients studied, and it took an average of 12.8 months for the disease to return or start growing again. After a typical follow-up of 18 months, 76.6 per cent of patients were still alive a year after treatment began — a striking figure for a cancer with the lowest survival rate of all common cancers in the UK, where about 11,500 people are diagnosed each year and about 10,200 die of the disease.

Daraxonrasib works by locking onto the mutated KRAS gene, which is found in more than nine in 10 pancreatic tumours and continuously signals cancer cells to grow. By switching that signal off, the drug can stop tumours growing. Dr Sam Godfrey of Cancer Research UK said the drug had found “a way of drugging the undruggable”, after years in which treatment for the disease had barely moved forward.

The drug, sold as Rasonque, is already approved in the United States for patients whose cancer has progressed after earlier treatment, following a larger late-stage trial. The new results come from an earlier-phase study testing it as a first treatment, combined with the chemotherapy drugs gemcitabine and nab-paclitaxel.

Doctors involved in the trial are careful to say the treatment is not a cure. The study was small and had no comparison group receiving chemotherapy alone, so it cannot yet show how much of the benefit is due to the pill itself. The results have not yet been published in a peer-reviewed journal, and a final phase-three trial is under way. Nobody yet knows how long the benefit lasts or whether the disease can be kept away for good.

For patients facing one of the deadliest forms of cancer, however, the results offer something that has been in short supply: real hope that a disease long considered almost untreatable may finally be yielding to targeted medicine.

Sources: European Organisation for Research and Treatment of Cancer (https://event.eortc.org/ena2026/2026/11/20/metastatic-pancreatic-cancer-responds-well-to-initial-treatment/) and BBC News reporting of the trial results. Note: this was a small, early-phase, single-arm trial with no comparison group, and the results are not yet peer-reviewed.

Leave a Reply

Your email address will not be published. Required fields are marked *